NuVasive Sales Slide on COVID and Supply Pressures

NuVasive reported 3Q21 orthopedic sales of $270.8 million, -8.3% vs. 3Q21 and -6.9% vs. 3Q19. Due to the impact of COVID and hospital staffing shortages on the remainder of the year, the company lowered its 2021 sales guidance to the range of $1.132 billion to $1.142 billion, representing a growth mid-point of +8.2% over 2020.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us